Will Uber Stock Recover?
Shares of Uber Technologies (NYSE:UBER) have had a rough few…
Sell
31
JAGX Quote, Financials, Valuation and Earnings
Last price:
$1.01
Seasonality move
:
-21.37%
Day range:
$1.00 - $1.08
52-week range:
$0.84 - $21.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.37x
P/B ratio:
0.87x
Volume:
376.2K
Avg. volume:
572.7K
1-year change:
-85.51%
Market cap:
$11.8M
Revenue:
$9.8M
EPS (TTM):
-$16.18
Analysts' Opinion
-
Consensus RatingJaguar Health has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.00, Jaguar Health has an estimated upside of 500% from its current price of $1.00.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $1.00.
Fair Value
-
According to the consensus of 1 analyst, Jaguar Health has 500% upside to fair value with a price target of $6.00 per share.
JAGX vs. S&P 500
-
Over the past 5 trading days, Jaguar Health has underperformed the S&P 500 by -6.44% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Jaguar Health does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Jaguar Health has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Jaguar Health reported revenues of $3.1M.
Earnings Growth
-
Jaguar Health has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Jaguar Health reported earnings per share of -$1.05.
Enterprise value:
31.2M
EV / Invested capital:
--
Price / LTM sales:
0.37x
EV / EBIT:
--
EV / Revenue:
2.97x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.07x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$8.4M
Return On Assets:
-69.52%
Net Income Margin (TTM):
-360.13%
Return On Equity:
-394.73%
Return On Invested Capital:
-87.16%
Operating Margin:
-233.66%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $10.8M | $10.7M | $10.5M | $2.8M | $3.1M | |
| Gross Profit | $8.8M | $8.9M | $8.4M | $2.3M | $2.6M | |
| Operating Income | -$39M | -$33M | -$29.9M | -$8.8M | -$7.3M | |
| EBITDA | -$40.4M | -$30.3M | -$29.6M | -$8.2M | -$6.7M | |
| Diluted EPS | -$3,774.06 | -$415.70 | -$16.18 | -$22.50 | -$1.05 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $10.7M | $24M | $25.2M | $22.1M | $36.6M | |
| Total Assets | $36.2M | $59.3M | $51.3M | $45.4M | $58.5M | |
| Current Liabilities | $25.8M | $12M | $26.9M | $12.5M | $19.9M | |
| Total Liabilities | $28.4M | $37.7M | $47.7M | $44M | $45.4M | |
| Total Equity | $7.8M | $21.6M | $3.6M | $1.4M | $13.1M | |
| Total Debt | $9.4M | $26.7M | $31.7M | $34.7M | $33.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$35.6M | -$32.2M | -$29M | -$6.8M | -$6.3M | |
| Cash From Investing | $9.2M | -- | -- | -- | -- | |
| Cash From Financing | $24.7M | $25.2M | $39M | $1.4M | $3.5M | |
| Free Cash Flow | -$36.9M | -$32.6M | -$29M | -$6.8M | -$6.3M | |
JAGX
Sector
Market Cap
$11.8M
$47.1M
Price % of 52-Week High
4.63%
48%
Dividend Yield
0%
0%
Shareholder Yield
-289.02%
-0.74%
1-Year Price Total Return
-85.51%
-33.14%
Beta (5-Year)
0.846
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.10
200-day SMA
Sell
Level
$3.65
Bollinger Bands (100)
Sell
Level
0.99 - 1.21
Chaikin Money Flow
Sell
Level
-820.7M
20-day SMA
Sell
Level
$1.03
Relative Strength Index (RSI14)
Sell
Level
47.13
ADX Line
Buy
Level
48.07
Williams %R
Neutral
Level
-68.7787
50-day SMA
Sell
Level
$1.02
MACD (12, 26)
Buy
Level
0.03
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
3B
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-10.1422)
Sell
CA Score
(Annual)
Level (-5.7428)
Buy
Beneish M-Score
(Annual)
Level (-3.1906)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (7.611)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Stock Forecast FAQ
In the current month, JAGX has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The JAGX average analyst price target in the past 3 months is $6.00.
-
Where Will Jaguar Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that Jaguar Health share price will rise to $6.00 per share over the next 12 months.
-
What Do Analysts Say About Jaguar Health?
Analysts are divided on their view about Jaguar Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Jaguar Health is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Jaguar Health's Price Target?
The price target for Jaguar Health over the next 1-year time period is forecast to be $6.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is JAGX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Jaguar Health is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of JAGX?
You can purchase shares of Jaguar Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Jaguar Health shares.
-
What Is The Jaguar Health Share Price Today?
Jaguar Health was last trading at $1.01 per share. This represents the most recent stock quote for Jaguar Health. Yesterday, Jaguar Health closed at $1.00 per share.
-
How To Buy Jaguar Health Stock Online?
In order to purchase Jaguar Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is ARK Next Generation Internet ETF a Good Investment?
The ARK Next Generation Internet ETF looks like a pretty…
Why Is Marvell Stock Up?
Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
